Dominika E Nanus1, Andrew D Filer2, Beverly Hughes3, Benjamin A Fisher2, Peter C Taylor4, Paul M Stewart3, Christopher D Buckley5, Iain McInnes6, Mark S Cooper7, Karim Raza5. 1. Rheumatology Research Group, University of Birmingham, Birmingham, UK Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, Birmingham, UK. 2. Rheumatology Research Group, University of Birmingham, Birmingham, UK Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. 3. Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, Birmingham, UK. 4. Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK. 5. Rheumatology Research Group, University of Birmingham, Birmingham, UK Department of Rheumatology, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK. 6. Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK. 7. Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, Birmingham, UK Anzac Research Institute, Concord Repatriation General Hospital, University of Sydney, Sydney, Australia.
Abstract
OBJECTIVE: To determine the relationship between inflammation and glucocorticoid metabolism in vivo, in a clinical study of patients with inflammatory arthritis treated with anti-TNFα therapy. METHODS: Urine samples were collected from patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) as part of a multicentre study assessing responses to infliximab and etanercept. Systemic measures of glucocorticoid metabolism were assessed by gas chromatography/mass spectrometry at weeks 0 (baseline), 4 and 12 after anti-TNFα therapy. Clinical data including DAS28 and C-reactive protein were also collected. RESULTS: Systemic measures of 11β-HSD1 activity in patients with inflammatory arthritis decreased significantly following anti-TNFα therapy in patients with RA and PsA. Additionally, the activity of the glucocorticoid inactivating enzyme 5α-reductase appeared to increase significantly. CONCLUSIONS: This study demonstrates, for the first time, that the increased 11β-HSD1 activity seen in patients with inflammatory arthritis is mediated through TNFα. Furthermore, the changes in related glucocorticoid metabolising enzymes suggest that there is a coordinated change in glucocorticoid metabolism which promotes higher tissue glucocorticoid levels. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
OBJECTIVE: To determine the relationship between inflammation and glucocorticoid metabolism in vivo, in a clinical study of patients with inflammatory arthritis treated with anti-TNFα therapy. METHODS: Urine samples were collected from patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) as part of a multicentre study assessing responses to infliximab and etanercept. Systemic measures of glucocorticoid metabolism were assessed by gas chromatography/mass spectrometry at weeks 0 (baseline), 4 and 12 after anti-TNFα therapy. Clinical data including DAS28 and C-reactive protein were also collected. RESULTS: Systemic measures of 11β-HSD1 activity in patients with inflammatory arthritis decreased significantly following anti-TNFα therapy in patients with RA and PsA. Additionally, the activity of the glucocorticoid inactivating enzyme 5α-reductase appeared to increase significantly. CONCLUSIONS: This study demonstrates, for the first time, that the increased 11β-HSD1 activity seen in patients with inflammatory arthritis is mediated through TNFα. Furthermore, the changes in related glucocorticoid metabolising enzymes suggest that there is a coordinated change in glucocorticoid metabolism which promotes higher tissue glucocorticoid levels. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: David Q Stoye; Ruth Andrew; William A Grobman; Emma K Adam; Pathik D Wadhwa; Claudia Buss; Sonja Entringer; Gregory E Miller; James P Boardman; Jonathan R Seckl; Lauren S Keenan-Devlin; Ann E B Borders; Rebecca M Reynolds Journal: J Clin Endocrinol Metab Date: 2020-03-01 Impact factor: 5.958
Authors: Dominika E Nanus; Andrew D Filer; Lorraine Yeo; Dagmar Scheel-Toellner; Rowan Hardy; Gareth G Lavery; Paul M Stewart; Christopher D Buckley; Jeremy W Tomlinson; Mark S Cooper; Karim Raza Journal: Arthritis Res Ther Date: 2015-05-14 Impact factor: 5.156
Authors: Janko Sattler; Jinwen Tu; Shihani Stoner; Jingbao Li; Frank Buttgereit; Markus J Seibel; Hong Zhou; Mark S Cooper Journal: Endocr Connect Date: 2018-01-31 Impact factor: 3.335
Authors: R S Hardy; C Fenton; A P Croft; A J Naylor; R Begum; G Desanti; C D Buckley; G Lavery; M S Cooper; K Raza Journal: J Autoimmun Date: 2018-06-08 Impact factor: 7.094
Authors: Michael S Sagmeister; Angela E Taylor; Anthony Fenton; Nadezhda A Wall; Dimitrios Chanouzas; Peter G Nightingale; Charles J Ferro; Wiebke Arlt; Paul Cockwell; Rowan S Hardy; Lorraine Harper Journal: Clin Endocrinol (Oxf) Date: 2018-11-15 Impact factor: 3.478